| CRMAX | FSMDX | CRMAX / FSMDX | |
| Total Expense Ratio | 1.24 | 0.03 | 4,960% |
| Annual Report Gross Expense Ratio | 1.24 | 0.03 | 4,960% |
| Fund Existence | 21 years | 14 years | - |
| Gain YTD | 6.361 | 3.683 | 173% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 2500 | 0 | - |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 145M | 46.9B | 0% |
| Annual Yield % from dividends | 0.28 | 1.07 | 26% |
| Returns for 1 year | 5.67 | 10.78 | 53% |
| Returns for 3 years | 8.49 | 39.55 | 21% |
| Returns for 5 years | -12.98 | 44.63 | -29% |
| Returns for 10 years | 7.77 | 187.08 | 4% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| GCIAX | 18.81 | 0.10 | +0.53% |
| Goldman Sachs Intl Eq Insghts A | |||
| ANVRX | 10.97 | 0.04 | +0.37% |
| American Century Non-US Intrs Val R | |||
| IVGAX | 20.52 | 0.03 | +0.15% |
| VY® Invesco Growth and Income A | |||
| PHPSX | 29.22 | 0.04 | +0.14% |
| ProFunds Pharmaceuticals UltraSector Svc | |||
| GLCTX | 30.75 | -0.64 | -2.04% |
| Goldman Sachs Large Cap Gr Insghts Inv | |||